Abstract
The development of nanocarriers able transport and release therapeutic agents in a controlled manner has provided a promising alternative in the oncology field due to the lack of selectivity of the conventional treatments. The encapsulation of cytotoxic compounds within nanoparticles improves the pharmacokinetic profile of the trapped drugs and allows their selective accumulation into the tumoral tissue owing to the enhance permeation and retention effect (EPR). In addition, the selectivity of the nanocarrier can be enhanced attaching targeting agents on their surface able to be specifically recognized by cancer cells or by the tumor microenvironment. Among the different materials which can be employed, mesoporous silica nanoparticles (MCM-41 type) constitutes a promising candidate due to their very interesting properties such as tuneable size, shape and porosity, high loading capacity, low toxicity, robustness and easiness fabrication and functionalization. This material presents a unique pore architecture which allows the synthesis of stimuliresponsive devices able to release the trapped drugs only in the presence of certain stimuli achieving a precise control on the drug dosage. This review presents some of the recent advances in the development of mesoporous silica nanocarriers for antitumoral therapy paying special attention on the stimuli-responsive systems able to release their load in response to external (light, magnetic field, temperature or ultrasounds) or internal stimulus (enzymes, pH, redox, among others).
Keywords: Antitumoral therapy, Drug delivery, Mesoporous silica nanoparticles, Nanomedicine, Smart materials, Stimuliresponsive release.
Current Topics in Medicinal Chemistry
Title:Smart Mesoporous Silica Nanocarriers for Antitumoral Therapy
Volume: 15 Issue: 22
Author(s): Alejandro Baeza and María Vallet-Regí
Affiliation:
Keywords: Antitumoral therapy, Drug delivery, Mesoporous silica nanoparticles, Nanomedicine, Smart materials, Stimuliresponsive release.
Abstract: The development of nanocarriers able transport and release therapeutic agents in a controlled manner has provided a promising alternative in the oncology field due to the lack of selectivity of the conventional treatments. The encapsulation of cytotoxic compounds within nanoparticles improves the pharmacokinetic profile of the trapped drugs and allows their selective accumulation into the tumoral tissue owing to the enhance permeation and retention effect (EPR). In addition, the selectivity of the nanocarrier can be enhanced attaching targeting agents on their surface able to be specifically recognized by cancer cells or by the tumor microenvironment. Among the different materials which can be employed, mesoporous silica nanoparticles (MCM-41 type) constitutes a promising candidate due to their very interesting properties such as tuneable size, shape and porosity, high loading capacity, low toxicity, robustness and easiness fabrication and functionalization. This material presents a unique pore architecture which allows the synthesis of stimuliresponsive devices able to release the trapped drugs only in the presence of certain stimuli achieving a precise control on the drug dosage. This review presents some of the recent advances in the development of mesoporous silica nanocarriers for antitumoral therapy paying special attention on the stimuli-responsive systems able to release their load in response to external (light, magnetic field, temperature or ultrasounds) or internal stimulus (enzymes, pH, redox, among others).
Export Options
About this article
Cite this article as:
Baeza Alejandro and Vallet-Regí María, Smart Mesoporous Silica Nanocarriers for Antitumoral Therapy, Current Topics in Medicinal Chemistry 2015; 15 (22) . https://dx.doi.org/10.2174/1568026615666150605114826
DOI https://dx.doi.org/10.2174/1568026615666150605114826 |
Print ISSN 1568-0266 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4294 |
Call for Papers in Thematic Issues
Chemistry Based on Natural Products for Therapeutic Purposes
The development of new pharmaceuticals for a wide range of medical conditions has long relied on the identification of promising natural products (NPs). There are over sixty percent of cancer, infectious illness, and CNS disease medications that include an NP pharmacophore, according to the Food and Drug Administration. Since NP ...read more
Current Trends in Drug Discovery Based on Artificial Intelligence and Computer-Aided Drug Design
Drug development discovery has faced several challenges over the years. In fact, the evolution of classical approaches to modern methods using computational methods, or Computer-Aided Drug Design (CADD), has shown promising and essential results in any drug discovery campaign. Among these methods, molecular docking is one of the most notable ...read more
Drug Discovery in the Age of Artificial Intelligence
In the age of artificial intelligence (AI), we have witnessed a significant boom in AI techniques for drug discovery. AI techniques are increasingly integrated and accelerating the drug discovery process. These developments have not only attracted the attention of academia and industry but also raised important questions regarding the selection ...read more
From Biodiversity to Chemical Diversity: Focus of Flavonoids
Flavonoids are the largest group of polyphenols, plant secondary metabolites arising from the essential aromatic amino acid phenylalanine (or more rarely from tyrosine) via the phenylpropanoid pathway. The flavan nucleus is the basic 15-carbon skeleton of flavonoids (C6-C3-C6), which consists of two phenyl rings (A and B) and a heterocyclic ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Editorial (Thematic Issue: Immunophilins, Protein Chemistry and Cell Biology of a Promising New Class of Drug Targets – Part II)
Current Molecular Pharmacology Advances in Photodynamic Therapy of Cancer
Current Cancer Therapy Reviews Radiosyntheses using Fluorine-18: The Art and Science of Late Stage Fluorination
Current Topics in Medicinal Chemistry Therapeutical Potential of CB<sub>2</sub> Receptors in Immune-Related Diseases
Current Molecular Pharmacology Cryptotanshinone Induces Pro-death Autophagy through JNK Signaling Mediated by Reactive Oxygen Species Generation in Lung Cancer Cells
Anti-Cancer Agents in Medicinal Chemistry Overview of Cantharidin and its Analogues
Current Medicinal Chemistry Conventional Anticancer Therapeutics and Telomere Maintenance Mechanisms
Current Pharmaceutical Design Hormetic Potential of Sulforaphane (SFN) in Switching Cells’ Fate Towards Survival or Death
Mini-Reviews in Medicinal Chemistry Studies on Chloride Channels and their Modulators
Current Topics in Medicinal Chemistry The Immunoregulatory Protein Human B7H3 is a Tumor-Associated Antigen that Regulates Tumor Cell Migration and Invasion
Current Cancer Drug Targets Radiation Induced Non-targeted Response: Mechanism and Potential Clinical Implications
Current Molecular Pharmacology Targeting Nanomedicine to Brain Tumors: Latest Progress and Achievements
Current Pharmaceutical Design Sp/KLF Family and Tumor Angiogenesis in Pancreatic Cancer
Current Pharmaceutical Design Emerging Use of Nanotechnology in the Treatment of Neurological Disorders
Current Pharmaceutical Design The Therapeutic Potential of Adenosine Triphosphate as an Immune Modulator in the Treatment of HIV/AIDS: A Combination Approach with HAART
Current HIV Research Phosphoinositide-3-kinases as the Novel Therapeutic Targets for the Inflammatory Diseases: Current and Future Perspectives
Current Drug Targets HSP27: Mechanisms of Cellular Protection Against Neuronal Injury
Current Molecular Medicine Imatinib Mesylate for the Treatment of Solid Tumours: Recent Trials and Future Directions
Current Enzyme Inhibition Inhibition of Mutated Isocitrate Dehydrogenase 1 in Cancer
Medicinal Chemistry Functional Roles of the Ca2+-activated K+ Channel, KCa3.1, in Brain Tumors
Current Neuropharmacology